MedPath

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Registration Number
NCT01415505
Lead Sponsor
Forest Laboratories
Brief Summary

The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
812
Inclusion Criteria
  • Male or female outpatients of age 18 years or above
  • Patients diagnosed with stage 1 or stage 2 essential hypertension
  • Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant
Exclusion Criteria
  • Secondary hypertension or severe hypertension
  • Clinically significant cardiovascular disease or heart failure
  • A medical contraindication to discontinuing a current antihypertensive therapy
  • History of Type 1 diabetes mellitus

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Nebivolol, Valsartan and HydrochlorothiazideNebivolol and Valsartan free tablet combination
Primary Outcome Measures
NameTimeMethod
Adverse Event RecordingFrom Baseline to Week 53 (Visit 16)
Secondary Outcome Measures
NameTimeMethod
Systolic Blood Pressure (SBP)From Baseline to Week 52 (Visit 15)
Diastolic Blood Pressure (DBP).From Baseline to Week 52 (Visit 15)

Trial Locations

Locations (135)

Forest Investigative Site 083

🇺🇸

Birmingham, Alabama, United States

Forest Investigative Site 004

🇺🇸

Foley, Alabama, United States

Forest Investigative Site 038

🇺🇸

Gulf Shores, Alabama, United States

Forest Investigative Site 124

🇺🇸

Muscle Shoals, Alabama, United States

Forest Investigative Site 023

🇺🇸

Chandler, Arizona, United States

Forest Investigative Site 073

🇺🇸

Goodyear, Arizona, United States

Forest Investigative Site 100

🇺🇸

Green Valley, Arizona, United States

Forest Investigative Site 117

🇺🇸

Mesa, Arizona, United States

Forest Investigative Site 065

🇺🇸

Mesa, Arizona, United States

Forest Investigative Site 102

🇺🇸

Phoenix, Arizona, United States

Scroll for more (125 remaining)
Forest Investigative Site 083
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.